JBM  Vol.4 No.12 , December 2016
Mutant Selection Windows of Azalomycin F5a in Combination with Vitamin K3 against Methicillin-Resistant Staphylococcus aureus
Abstract: Azalomycin F5a, a 36-membered macrocyclic lactone isolated from several streptomyces strains, presented remarkable anti-methicillin-resistant Staphylococcus aureus (MRSA) activities. To improve its anti-MRSA potential and to evaluate the probability of MRSA resistant to it before development, the anti-MRSA activities of azalomycin F5a in combination with vitamin K3 were first evaluated using checkerboard assay. Then the minimal concentration inhibiting colony formation by 99% (MIC99) and mutant prevention concentration (MPC) of azalomycin F5a alone and in combination with vitamin K3 against MRSA were determined using agar plates with linear antimicrobial concentration decrease. The fractional inhibitory concentration indexes (FICIs) of 0.25 - 0.50 showed the synergistic activity of azalomycin F5a in combination with vitamin K3. The mutant selection windows (MSWs, MIC99-MPC) of azalomycin F5a alone against MRSA tested were 2.07 - 6.40 μg/mL, and the MPCs of azalomycin F5a in combination with vitamin K3 against MRSA tested were 1.60 - 3.20 μg/mL. These indicated that the MPCs of azalomycin F5a in combination could drop down to below its MIC99 alone. According to the hypothesis of MSW, the narrower MSWs of azalomycin F5a alone, even closed MSWs in combination with vitamin K3, together with their synergistic anti-MRSA activities, indicated that azalomycin F5a had a good potential to develop as a new antimicrobial agent.
Cite this paper: Xu, X. , Wu, X. , Yuan, G. , Xu, L. and Wang, Y. (2016) Mutant Selection Windows of Azalomycin F5a in Combination with Vitamin K3 against Methicillin-Resistant Staphylococcus aureus. Journal of Biosciences and Medicines, 4, 162-174. doi: 10.4236/jbm.2016.412020.

[1]   Cassir, N., Rolain, J. and Brouqui, P. (2014) A New Strategy to Fight Antimicrobial Resistance: The Revival of Old Antibiotics. Front Microbiology, 5, 551.

[2]   Vestergaard, M., Paulander, W., Marvig, R.L., Clasen, J., Jochumsen, N., Molin, S., Jelsbak, L., Ingmer, H. and Folkesson, A. (2016) Antibiotic Combination Therapy Can Select for Broad-spectrum Multidrug Resistance in Pseudomonas aeruginosa. International Journal of Antimicrobial Agents, 47, 48-55.

[3]   Baquero, F. and Negri, M.C. (1997) Strategies to Minimize the Development of Antibiotic Resistance. Journal of Chemotherapy, 9, 29-37.

[4]   Dong, Y., Zhao, X., Domagala, J. and Drlica, K. (1999) Effect of Fluoroquinolone Concentration on Selection of Resistant Mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrobial Agents Chemotherapy, 43, 1756-1758.

[5]   Drlica, K. and Zhao, X. (2007) Mutant Selection Window Hypothesis Updated. Clinical Infectious Diseases, 44, 681-688.

[6]   Allen, G.P. and Deshpande, L.M. (2010) Determination of the Mutant Selection Window for Clindamycin, Doxycycline, Linezolid, Moxifloxacin and Trimethoprim/Sulfamethoxazole against Community-associated Meticillin-resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents, 35, 45-49.

[7]   Zhanel, G.G., Mayer, M., Laing, N. and Adam, H.J. (2006) Mutant Prevention Concentrations of Levofloxacin Alone and in Combination with Azithromycin, Ceftazidime, Colistin (Polymyxin E), Meropenem, Piperacillin-tazobactam, and Tobramycin against Pseudomonas aeruginosa. Antimicrobial Agents Chemotherapy, 50, 2228-2230.

[8]   Zhao, X., Eisner, W., Perl-Rosenthal, N., Kreiswirth, B. and Drlica, K. (2003) Mutant Prevention Concentration of Garenoxacin (BMS-284756) for Ciprofloxacin-Susceptible or -Resistant Staphylococcus aureus. Antimicrobial Agents Chemotherapy, 47, 1023-1027.

[9]   Johnson, D.E. and Thompson, B. (1986) Efficacy of Single-agent Therapy with Azlocillin, Ticarcillin, and Amikacin and Beta-Lactam/Amikacin Combinations for Treatment of Pseudomonas aeruginosa Bacteremia in Granulocytopenic Rats. American Journal of Medicine, 80, 53-58.

[10]   Iwasaki, S., Namikoshi, M., Sasaki, K., Fukushima, K. and Okuda, S. (1982) Studies on Macrocyclic Lactone Antibotics. V. The Structures of Azalomycins F3a and F5a. Chemical and Pharmaceutical Bulletin, 30, 4006-4014.

[11]   Jackson, C., Agboke, A. and Nwoke, V. (2009) In Vitro Evaluation of Antimicrobial Activity of Combinations of Nystatin and Euphorbia hirta Leaf Extract against Candida albicans by the Checkerboard Method. Journal of Medicinal Plants Research, 3, 666-669.

[12]   Yuan, G., Li, P., Pan, W., Pang, H. and Chen, S. (2013) The Relative Configurations of Azalomycins F5a, F4a and F3a. Journal of Molecular Structure, 1035, 31-37.

[13]   Yuan, G., Li, P., Yang, J., Pang, H. and Pei, Y. (2014) Anti-Methicillin-Resistant Staphylococcus aureus Assay of Azalomycin F5a and Its Derivatives. Chinese Journal of Natural Medicines, 12, 309-313.

[14]   Yuan, G., Zhu, X., Li, P., Zhang, Q. and Cao, J. (2014) New Activity for Old Drug: In Vitro Activities of Vitamin K3 and Menadione Sodium Bisulfite against Methicillin-Resistant Staphylococcus aureus. African Journal of Pharmacy and Pharmacology, 8, 451-454.

[15]   Yuan, G., Lin, H., Wang, C., Hong, K., Liu, Y. and Li, J. (2011) 1H and 13C Assignments of Two New Macrocyclic Lactones Isolated from Streptomyces sp. 211726 and Revised Assignments of Azalomycins F3a, F4a and F5a. Magnetic Resonance in Chemistry, 49, 30-37.

[16]   Clinical and Laboratory Standards Institute (CLSI) (2012) CLSI Document M07-A9. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard. 19th Edition, CLSI, Wayne.

[17]   Firsov, A.A., Smirnova, M.V., Strukova, E.N., Vostrov, S.N., Portnoy, Y.A. and Zinner, S.H. (2008) Enrichment of Resistant Staphylococcus aureus at Ciprofloxacin Concentrations Simulated within the Mutant Selection Window: Bolus versus Continuous Infusion. International Journal of Antimicrobial Agents, 32, 488-493.

[18]   Zhao, X. and Drlica, K. (2002) Restricting the Selection of Antibiotic-Resistant Mutants: Measurement and Potential Uses of the Mutant Selection Window. Journal of Infectious Diseases, 185, 561-565.

[19]   Kuroda, S., Uno, J. and Arai, T. (1978) Target Substances of Some Antifungal Agents in the Cell Membrane. Antimicrobial Agents Chemotherapy, 13, 454-459.

[20]   Sindelar, G., Zhao, X., Liew, A., Dong, Y., Lu, T., Zhou, J., Domagala, J. and Drlica, K. (2000) Mutant Prevention Concentration as a Measure of Fluoroquinolone Potency against Mycobacteria. Antimicrobial Agents Chemotherapy, 44, 3337-3343.

[21]   Fischbach, M.A. (2011) Combination Therapies for Combating Antimicrobial Resistance. Current Opinion in Microbiology, 14, 519-523.

[22]   Tamma, P.D., Cosgrove, S.E. and Maragakis, L.L. (2012) Combination Therapy for Treatment of Infections with Gram-Negative Bacteria. Clinical Microbiology Reviews, 25, 450-470.

[23]   Saey, T.H. (2011) Antibiotics May Make Fighting Flu Harder. Science News.

[24]   LaFleur, M.D., Kumamoto, C.A. and Lewis, K. (2006) Candida albicans Biofilms Produce Antifungal-Tolerant Persister Cells. Antimicrobial Agents Chemotherapy, 50, 3839-3846.

[25]   Lechner, S., Lewis, K. and Bertram, R. (2012) Staphylococcus aureus Persisters Tolerant to Bactericidal Antibiotics. Journal of Molecular Microbiology and Biotechnology, 22, 235-244.

[26]   Lewis, K. (2008) Multidrug Tolerance of Biofilms and Persister Cells. Current Topics Microbiology and Immunology, 322, 107-131.

[27]   Singh, R., Ray, P., Das, A. and Sharma, M. (2009) Role of Persisters and Small-Colony Variants in Antibiotic Resistance of Planktonic and Biofilm-Associated Staphylococcus aureus: An in Vitro Study. Journal of Medical Microbiology, 58, 1067-1073.

[28]   Robertson, G.T., Bonventre, E.J., Doyle, T.B., Du, Q., Duncan, L., Morris, T.W., Roche, E.D., Yan, D. and Lynch, A.S. (2008) In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Microbiology Profiling Studies with Staphylococci and Streptococci. Antimicrobial Agents Chemotherapy, 52, 2324-2334.